Testing camoteskimab for moderate-to-severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to creams alone. The drug works by targeting a protein in the body that causes eczema symptoms like itching and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have had eczema for at least 1 year that affects at least 10% of your skin
- Your eczema is moderate-to-severe and causes significant itching (at least 4 out of 10)
- Topical creams and ointments haven't worked well for you, or you can't use them safely
- You are willing to avoid certain eczema medications for 1–12 weeks before and during the study
- You do not have HIV, hepatitis B or C, tuberculosis, or a recent cancer diagnosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.